/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA).
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
TOKYO, May 12, 2023 /PRNewswire/ Astellas Pharma Inc. today. | June 14, 2023
Results for Astellas' non-hormonal menopause drug published in The Lancet pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.